Celltrion has received approval from the US Food and Drug Administration for the sale of an oral antiviral drug, Demixis Steam, for the treatment of human immunodeficiency virus (HIV-1) infections.
Temmics is an amendment that combines GSK's antiviral drug, "Jeffix", with antiviral & Virtue & # 39; by Gillard. Started to develop in 2016, the application was approved by the US FDA in January this year. In Korea, Celltrion Pharmaceutical received approval for export drugs from the Korea Food and Drug Administration (KFDA) last month.
It will be released in the US market early next year. It provides reasonable prices for HIV patients who find it difficult to provide drugs because of the high insurance structure and US price. We will also provide the World Health Organization (WHO) and other leading HIV treatment providers worldwide.
The HIV treatment market in the US is estimated at about W24tr. Temmics will compete in the market of 3.3 trillion won.[전자신문 CIOBIZ] Journalist Jung Yong-cheol medical / biotech [email protected]